Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Subsidiary Using Synthetic Biology Platform from Sloning

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German biotech firm MorphoSys today announced an agreement between its recently acquired subsidiary Sloning BioTechnology and Pfizer for use of Sloning's synthetic biology technology.

Sloning will install its Slonomics platform at Pfizer's subsidiary Rinat Neuroscience in South San Francisco, Calif. Sloning will also provide training and use of the platform. Rinat has been using Sloning's services since 2009, Jaume Pons, chief scientific officer for Rinat, said in a statement.

Sloning will receive an upfront payment for an undisclosed amount in 2010, and licensing fees of the patent lifetime of the Slonomics technology, MorphoSys said.

Further financial and other terms of the deal were not disclosed.

MorphoSys acquired Sloning in October for €19 million ($25 million).

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.